EUVIMEDEUVIMED entdecken
Crossref

The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer

Journal of Chinese Pharmaceutical Sciences · 30.03.2026 · 35 (3) · 292

DOI: 10.5246/jcps.2026.03.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chinese Pharmaceutical Sciences, online erschienen am 10.03.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer. Journal of Chinese Pharmaceutical Sciences, 35(3), 292. https://doi.org/10.5246/jcps.2026.03.020

Vancouver

The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer. Journal of Chinese Pharmaceutical Sciences. 2026;35(3):292. doi:10.5246/jcps.2026.03.020

BibTeX
@article{euvimed2026,
  title = {The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer},
  journal = {Journal of Chinese Pharmaceutical Sciences},
  year = {2026},
  volume = {35},
  number = {3},
  pages = {292},
  doi = {10.5246/jcps.2026.03.020}
}
Kostenlos starten →